Takeda Pharmaceutical (TAK) total liabilities
Takeda Pharmaceutical (TAK) had total liabilities of ¥8.08T at the end of fiscal 2026 (March 31, 2026). That is 10.5% higher than the ¥7.31T of fiscal 2025. Figures as of 18 Nov 2026, 18:27 UTC, from Yahoo Finance.
Key facts
- Total liabilities, fiscal 2026
- ¥8.08T
- Change on fiscal 2025
- +10.5%
- Highest on record
- ¥8.08Tfiscal 2026
- Lowest on record
- ¥7.31Tfiscal 2025
- Fiscal years on record
- 42023–2026
Figures as of . Statements from Yahoo Finance. Amounts are in JPY. Figures, not advice.
Takeda Pharmaceutical total liabilities, in more detail
Across the 4 fiscal years on record (2023–2026), the highest was ¥8.08T in fiscal 2026 and the lowest ¥7.31T in fiscal 2025.
Total liabilities by fiscal year
Takeda Pharmaceutical total liabilities, year by year
| Fiscal year | Total liabilities | Change | Year ended |
|---|---|---|---|
| 2026 | ¥8.08T | 10.5% up | |
| 2025 | ¥7.31T | 6.7% down | |
| 2024 | ¥7.83T | 3.0% up | |
| 2023 | ¥7.60T | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.
How to read it
It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.
Total liabilities at health care companies of similar size
| Company | Total liabilities | Fiscal year |
|---|---|---|
| Takeda Pharmaceutical TAK | ¥8.08T | 2026 |
| Cencora COR | $74.84B | 2025 |
| Boston Scientific BSX | $19.20B | 2025 |
| Cardinal Health CAH | $60.02B | 2026 |
| argenx ARGX | $1.36B | 2025 |
| Edwards Lifesciences EW | $3.36B | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Takeda Pharmaceutical, figure by figure
- Takeda Pharmaceutical market cap
- Takeda Pharmaceutical revenue
- Takeda Pharmaceutical earnings
- Takeda Pharmaceutical earnings per share (EPS)
- Takeda Pharmaceutical P/E ratio
- Takeda Pharmaceutical P/S ratio
- Takeda Pharmaceutical P/B ratio
- Takeda Pharmaceutical free cash flow
- Takeda Pharmaceutical operating margin
- Takeda Pharmaceutical dividend
- Takeda Pharmaceutical shares outstanding
- Takeda Pharmaceutical total debt
- Takeda Pharmaceutical cash on hand
- Takeda Pharmaceutical total assets
- Takeda Pharmaceutical net assets (shareholders' equity)
- Takeda Pharmaceutical return on equity (ROE)
- Takeda Pharmaceutical return on invested capital (ROIC)
Takeda Pharmaceutical (TAK) overview: price, valuation and scorecardAll health care companies by market value
Takeda Pharmaceutical total liabilities: questions and answers
How large are Takeda Pharmaceutical's total liabilities?
Takeda Pharmaceutical (TAK) had total liabilities of ¥8.08T at the end of fiscal 2026 (March 31, 2026). That is 10.5% higher than the ¥7.31T of fiscal 2025.
What are the highest and lowest total liabilities figures on record for Takeda Pharmaceutical?
Across the 4 fiscal years on record (2023–2026), the highest was ¥8.08T in fiscal 2026 and the lowest ¥7.31T in fiscal 2025.
How is Takeda Pharmaceutical's total liabilities calculated?
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For Takeda Pharmaceutical it is on record here for 4 fiscal years, 2023 to 2026.
Fiscal years are named for the calendar year they end in.
Learn: total liabilities
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Takeda Pharmaceutical (TAK) total liabilities”, data as of 18 November 2026. https://funkfolio.com/stock/TAK/total-liabilities
Underlying data: Yahoo Finance.